A company in the US has just announced that they have a genetic test for suicide ideation (having suicidal thoughts), which could be used in conjunction with depression medication (Citalopram) in order to identify appropriate candidates for the medication.

The test is called the Mark-C test and the company is from Boulder Colorado and is called NeuroMark.

Their website doesn’t have much on it so far.